Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.

MLA

Cortes, Jorge, et al. “Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared with Allopurinol Alone--Results of a Multicenter Phase III Study.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 28, no. 27, Sept. 2010, pp. 4207–13. EBSCOhost, https://doi.org/10.1200/JCO.2009.26.8896.

APA

Cortes, J., Moore, J. O., Maziarz, R. T., Wetzler, M., Craig, M., Matous, J., Luger, S., Dey, B. R., Schiller, G. J., Pham, D., Abboud, C. N., Krishnamurthy, M., Brown, A., Jr, Laadem, A., & Seiter, K. (2010). Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 28(27), 4207–4213. https://doi.org/10.1200/JCO.2009.26.8896

Chicago

Cortes, Jorge, Joseph O Moore, Richard T Maziarz, Meir Wetzler, Michael Craig, Jeffrey Matous, Selina Luger, et al. 2010. “Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared with Allopurinol Alone--Results of a Multicenter Phase III Study.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28 (27): 4207–13. doi:10.1200/JCO.2009.26.8896.